{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:23:04Z","timestamp":1776219784378,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C60293\/A28497"],"award-info":[{"award-number":["C60293\/A28497"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bbi.2024.03.023","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T22:45:07Z","timestamp":1710715507000},"page":"468-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3734-0792","authenticated-orcid":false,"given":"Harrison D.","family":"Collier-Bain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Causer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frankie F.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Graby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Eddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rothschild-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet C.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstie L.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2024.03.023_b0005","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1152\/jappl.1986.60.6.2020","article-title":"A new method for detecting anaerobic threshold by gas exchange","volume":"121","author":"Beaver","year":"1986","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.bbi.2024.03.023_b0010","doi-asserted-by":"crossref","first-page":"e11966","DOI":"10.1371\/journal.pone.0011966","article-title":"NK cell terminal differentiation: Correlated stepwise decrease of NKG2A and acquisition of KIRs","volume":"5","author":"B\u00e9ziat","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbi.2024.03.023_b0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbi.2013.10.030","article-title":"Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells","volume":"39","author":"Bigley","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.03.023_b0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","article-title":"Psychophysical bases of perceived exertion","volume":"14","author":"Borg","year":"1982","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.bbi.2024.03.023_b0025","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbi.2024.03.023_b0030","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2024.03.023_b0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2024.03.023_b0040","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/ refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2024.03.023_b0045","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","article-title":"Intraclonal complexity in chronic lymphocytic leukemia: Fractions enriched in recently born\/divided and older\/quiescent cells","volume":"17","author":"Calissano","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbi.2024.03.023_b0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbi.2009.02.011","article-title":"Acute exercise mobilises CD8+ T lymphocytes exhibiting an effector-memory phenotype","volume":"23","author":"Campbell","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.03.023_b0055","doi-asserted-by":"crossref","first-page":"1244090","DOI":"10.3389\/fonc.2023.1244090","article-title":"Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review","volume":"13","author":"Collier-Bain","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbi.2024.03.023_b0060","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2015.124693","article-title":"Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the german CLL study group (GCLLSG)","volume":"100","author":"Cramer","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bbi.2024.03.023_b0065","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"De Weerdt","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbi.2024.03.023_b0070","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbi.2024.03.023_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.788113","article-title":"Reframing how physical activity reduces the incidence of clinically-diagnosed cancers: appraising exercise-induced immuno-modulation as an integral mechanism","volume":"12","author":"Emery","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbi.2024.03.023_b0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2003.11.011","article-title":"Effects of repeated social stress on leukocyte distribution in bone marrow, peripheral blood and spleen","volume":"148","author":"Engler","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2024.03.023_b0085","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/leu.2013.190","article-title":"Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab","volume":"27","author":"Fink","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbi.2024.03.023_b0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2024.03.023_b0095","doi-asserted-by":"crossref","unstructured":"G\u0308or\u0308gun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013;121:2975\u201387. https:\/\/doi.org\/10.1182\/BLOOD-2012-08-448548.","DOI":"10.1182\/blood-2012-08-448548"},{"key":"10.1016\/j.bbi.2024.03.023_b0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbi.2018.08.017","article-title":"\u03b22-adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans","volume":"74","author":"Graff","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.03.023_b0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bbi.2018.04.007","article-title":"Autologous serum collected 1 h post-exercise enhances natural killer cell cytotoxicity","volume":"71","author":"Gupta","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2024.03.023_b0110","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbi.2024.03.023_b0115","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbi.2024.03.023_b0120","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2024.03.023_b0125","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2024.03.023_b0130","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2024.03.023_b0135","unstructured":"HMRN. HMRN - Incidence 2019. https:\/\/hmrn.org\/statistics\/incidence (accessed October 10, 2023)."},{"key":"10.1016\/j.bbi.2024.03.023_b0140","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10555-005-6192-2","article-title":"Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies","volume":"24","author":"Iannello","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbi.2024.03.023_b0145","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s12185-019-02788-7","article-title":"Pathophysiology of chronic lymphocytic leukemia and human B1 cell development","volume":"111","author":"Kikushige","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bbi.2024.03.023_b0150","first-page":"1","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbi.2024.03.023_b0155","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.bbi.2024.03.023_b0160","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1177\/0091270011430506","article-title":"Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbi.2024.03.023_b0165","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset","volume":"116","author":"Lopez-Verg\u00e8s","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2024.03.023_b0170","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbi.2024.03.023_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbi.2024.03.023_b0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbi.2024.03.023_b0185","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bbi.2024.03.023_b0190","doi-asserted-by":"crossref","first-page":"68513","DOI":"10.18632\/oncotarget.12097","article-title":"NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma","volume":"7","author":"Parry","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbi.2024.03.023_b0195","doi-asserted-by":"crossref","unstructured":"Pasikowska M, Walsby E, Apollonio B, Cuthill K, Phillips E, Coulter E, et al. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood 2016;128:563\u201373. https:\/\/doi.org\/10.1182\/BLOOD-2016-01-683128.[38] Zucchetto A, Bomben R, Dal Bo M, Bulian P, Benedetti D, Nanni P, et al. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia 2006 20:3 2006;20:523\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2404087.","DOI":"10.1038\/sj.leu.2404087"},{"key":"10.1016\/j.bbi.2024.03.023_b0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.170.2.481","article-title":"Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions","volume":"170","author":"Ravetch","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbi.2024.03.023_b0205","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbi.2024.03.023_b0210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00007256-200333040-00002","article-title":"Adhesion molecules, catecholamines and leucocyte redistribution during and following exercise","volume":"33","author":"Shephard","year":"2003","journal-title":"Sports Med."},{"key":"10.1016\/j.bbi.2024.03.023_b0215","doi-asserted-by":"crossref","unstructured":"Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the Regulation of Immune Functions. Prog Mol Biol Transl Sci, vol. 135, Elsevier B.V.; 2015, p. 355\u201380. https:\/\/doi.org\/10.1016\/bs.pmbts.2015.08.001.","DOI":"10.1016\/bs.pmbts.2015.08.001"},{"key":"10.1016\/j.bbi.2024.03.023_b0220","doi-asserted-by":"crossref","unstructured":"Smith A, Howell D, Crouch S, Painter D, Blase J, Wang HI, et al. Cohort profile: The Haematological malignancy Research Network (HMRN): A UK population-based patient cohort. Int J Epidemiol 2018;47:700-700G. https:\/\/doi.org\/10.1093\/ije\/dyy044.","DOI":"10.1093\/ije\/dyy044"},{"key":"10.1016\/j.bbi.2024.03.023_b0225","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2018.78.7390","article-title":"Deleting malignant B cells with second-generation anti-CD20 antibodies","volume":"36","author":"Sopp","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbi.2024.03.023_b0230","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","article-title":"Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor\u2013mediated natural killer cell function","volume":"24","author":"Stiff","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbi.2024.03.023_b0235","first-page":"338","article-title":"Revision of the physical activity readiness questionnaire (PAR-Q)","volume":"17","author":"Thomas","year":"1992","journal-title":"Can. J. Sport Sci."},{"key":"10.1016\/j.bbi.2024.03.023_b0240","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41375-018-0132-y","article-title":"Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies","volume":"32","author":"Thompson","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbi.2024.03.023_b0245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.physbeh.2016.06.023","article-title":"Exercise-induced B cell mobilisation: Preliminary evidence for an influx of immature cells into the bloodstream","volume":"164","author":"Turner","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.bbi.2024.03.023_b0250","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1158\/0008-5472.CAN-17-2344","article-title":"Slan+ monocytes and macrophages mediate CD20-dependent b-cell lymphoma elimination via ADCC and ADCP","volume":"78","author":"Vermi","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbi.2024.03.023_b0255","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1189\/jlb.0912461","article-title":"Blood CD33(+)HLA-DR(\u2212) myeloid-derived suppressor cells are increased with age and a history of cancer","volume":"93","author":"Verschoor","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbi.2024.03.023_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/srep34310","article-title":"CD16 is indispensable for antibodydependent cellular cytotoxicity by human monocytes","volume":"6","author":"Yeap","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbi.2024.03.023_b0265","doi-asserted-by":"crossref","unstructured":"Zucchetto A, Bomben R, Dal Bo M, Bulian P, Benedetti D, Nanni P, et al. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia 2006 20:3 2006;20:523\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2404087.","DOI":"10.1038\/sj.leu.2404087"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159124003040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159124003040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:08:45Z","timestamp":1742180925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159124003040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":53,"alternative-id":["S0889159124003040"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2024.03.023","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2024.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}